Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract IA010: Molecular archeology of cancer

View through CrossRef
Abstract Tumor development is driven by changes to the genome leading to fitness advantages underlying successive clonal expansions. As somatic changes occur across most or all cell cycles, the cancer genome carries an archeological record of its past. Over the past years, we have developed several approaches to mine that archeological record from the cancer genome, which we collectively call 'molecular archeology of cancer'. Using these approaches, we are able to infer the subclonal architecture of tumors and gain key insights into the order and timing of the genomic changes that occurred over their evolutionary history. We have applied these approaches in a large-scale pan-cancer setting, showing that intra-tumor heterogeneity is pervasive across cancers and that the timelines of tumor evolution span multiple years to decades. Key driver events in tumor evolution typically occur early, and copy number gains often accumulate as punctuated bursts, commonly after genome doubling. Late genome doubling is frequent in cancer evolution and is typically followed by an increase in the rate of copy number gains. Genome duplications affect the selection landscape of copy number losses, while only minimally impacting copy number gains. Extending our timing framework to time mutational signatures, we find that, as expected, environmentally associated mutations are associated with early tumor development. We also find evidence of episodic APOBEC mutagenesis across many tumors and clear timing patterns in many mutational processes that have unknown origins. Our approaches increase the evolutionary information that can be obtained from tumor genome sequences and, therefore, improve our understanding of the developmental history of cancer. Citation Format: Peter Van Loo. Molecular archeology of cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl):Abstract nr IA010.
American Association for Cancer Research (AACR)
Title: Abstract IA010: Molecular archeology of cancer
Description:
Abstract Tumor development is driven by changes to the genome leading to fitness advantages underlying successive clonal expansions.
As somatic changes occur across most or all cell cycles, the cancer genome carries an archeological record of its past.
Over the past years, we have developed several approaches to mine that archeological record from the cancer genome, which we collectively call 'molecular archeology of cancer'.
Using these approaches, we are able to infer the subclonal architecture of tumors and gain key insights into the order and timing of the genomic changes that occurred over their evolutionary history.
We have applied these approaches in a large-scale pan-cancer setting, showing that intra-tumor heterogeneity is pervasive across cancers and that the timelines of tumor evolution span multiple years to decades.
Key driver events in tumor evolution typically occur early, and copy number gains often accumulate as punctuated bursts, commonly after genome doubling.
Late genome doubling is frequent in cancer evolution and is typically followed by an increase in the rate of copy number gains.
Genome duplications affect the selection landscape of copy number losses, while only minimally impacting copy number gains.
Extending our timing framework to time mutational signatures, we find that, as expected, environmentally associated mutations are associated with early tumor development.
We also find evidence of episodic APOBEC mutagenesis across many tumors and clear timing patterns in many mutational processes that have unknown origins.
Our approaches increase the evolutionary information that can be obtained from tumor genome sequences and, therefore, improve our understanding of the developmental history of cancer.
Citation Format: Peter Van Loo.
Molecular archeology of cancer [abstract].
In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl):Abstract nr IA010.

Related Results

Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Diagnostic Rate of the Cancer by BDORT Utilizing the Cancer Slide
Diagnostic Rate of the Cancer by BDORT Utilizing the Cancer Slide
Purpose: To make a diagnosis of cancer with BDORT (resonance test), we can choose two methods. One is to use a chemical agent like Integrin α5β1 or Oncogene C-f...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
Abstract IA010: Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans
Abstract IA010: Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans
Abstract Immune checkpoint blockade has revolutionized cancer treatment, but resistance remains a significant hurdle for many patients. Sialoglycans, as new immune c...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...

Back to Top